grant
Molecular basis and protective efficacy of cross-neutralizing antibodies against four major respiratory viruses
Organization FRED HUTCHINSON CANCER CENTERLocation SEATTLE, UNITED STATESPosted 16 Mar 2023Deadline 29 Feb 2028
NIHUS FederalResearch GrantFY202621+ years oldAdultAdult HumanAnimal ModelAnimal Models and Related StudiesAnimalsAntibodiesAntibody Binding SitesAntibody TherapyAntigenic DeterminantsAntigensB blood cellsB cellB cellsB-CellsB-LymphocytesB-cellBindingBinding DeterminantsBioavailabilityBiological AvailabilityBloodBlood Reticuloendothelial SystemBlood SerumCancersCell IsolationCell SegregationCell SeparationCell Separation TechnologyChildhoodClinicalClinical Treatment MoabClinical TrialsCommunitiesCricetinaeDNA mutationData BasesDatabasesDevelopmentDiseaseDisorderDoseDrug KineticsDrug TherapyEpitopesEscape MutantEvolutionFailureFrequenciesFutureGenetic ChangeGenetic defectGenetic mutationHPIV1HPIV3HSC transplantationHalf-LifeHamstersHamsters MammalsHemadsorption Type 2 VirusHemadsorption Virus 1Hemadsorption Virus 2Hematopoietic Stem Cell TransplantHematopoietic Stem Cell TransplantationHistopathologyHumanHuman MetapneumovirusHuman Parainfluenza Virus 1Human Parainfluenza Virus 3Immune systemImmunityImmunocompetentImmunocompromisedImmunocompromised HostImmunocompromised PatientImmunosuppressed HostImmunosuppressionImmunosuppression EffectImmunosuppressive EffectIn VitroInfantInfectionKnowledgeLavageLifeLower Respiratory Tract InfectionLower respiratory infectionLungLung Respiratory SystemLung infectionsMagnetismMalignant NeoplasmsMalignant TumorMapsMeasuresMethodsModelingModern ManModificationMolecularMolecular InteractionMonitorMonoclonal AntibodiesMutationNasalNasal Lavage FluidNasal Passages NoseNasal WashingNasal WashingsNosePara-Influenza Virus Type 1Para-Influenza Virus Type 3ParatopesPassive ImmunizationPatientsPersonsPharmacokineticsPharmacological TreatmentPharmacotherapyPhasePhysiologic AvailabilityPositionPositioning AttributePost-vaccination infectionPreclinical dataPreventionPreventiveProgenitor Cell TransplantationProphylactic treatmentProphylaxisResearchResearch ResourcesResistanceResourcesRespiratory System, Nose, Nasal PassagesRespiratory syncytial virusRisk ReductionSerumSiteStem Cell TransplantationStem cell transplantTarget PopulationsTechniquesTestingTherapeuticTimeTracheaTrachea ProperTransplant RecipientsTransplantationTreatment EfficacyVariantVariationViralViral AntigensViral Respiratory Tract InfectionVirusVirus ReplicationWorkadulthoodanti-cancer researchantibody based therapiesantibody combining siteantibody treatmentantibody-based therapeuticsantibody-based treatmentblood stem cell transplantationbreakthrough infectioncancer researchcell sortingclinical developmentclinical efficacycombatdata basedeep sequencingdesigndesigningdevelopmentaldrug interventiondrug treatmentefficacy testingexperiencefitnessgenome mutationhematopoietic cell transplantationhematopoietic cellular transplantationhematopoietic progenitor cell transplantationimmune competentimmune suppressionimmune suppressive activityimmune suppressive functionimmunogenimmunosuppressed patientimmunosuppressive activityimmunosuppressive functionimmunosuppressive responsein vivoinfection riskinnovateinnovationinnovativeintervention efficacylavage therapymAbsmagneticmalignancymodel of animalmonoclonal Absmortalitymutantmutation scanningmutation screeningneglectneoplasm/cancerneutralizing antibodyneutralizing mAbneutralizing monoclonal antibodiesnext generationnon-human primatenonhuman primatenovelparainfluenza virusparainfluenza virus type 1parainfluenza virus type 3passive vaccinationpediatricpharmaceutical interventionpharmacological interventionpharmacological therapypharmacology interventionpharmacology treatmentpharmacotherapeuticspost-transplantpost-transplantationposttransplantposttransplantationpre-clinicalpre-clinical evaluationpreclinicalpreclinical evaluationpreclinical findingspreclinical informationpreventpreventingprogenitor transplantationprophylacticprotective efficacypulmonarypulmonary infectionsreduce riskreduce risksreduce that riskreduce the riskreduce these risksreduces riskreduces the riskreducing riskreducing the riskresistantrespiratoryrespiratory virusrisk-reducingscreeningscreeningsstandard of carestem and progenitor cell transplantationssuccesstherapeutic efficacytherapy efficacytransplanttransplant patientviral fitnessviral multiplicationviral replicationviral resistanceviral respiratory infectionvirtualvirus antigenvirus multiplicationvirus resistancewindpipe
Description preview
PROJECT SUMMARY/ABSTRACT
Tens of thousands of otherwise deadly cancers are cured worldwide each year by hematopoietic stem cell
transplantation (HCT), but unfortunately over one in ten patients will develop a viral lower respiratory tract
infection, with almost half of these patients succumbing to the infection. Without an intact immune system in…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click